What is Rivia?
Rivia operates at the intersection of artificial intelligence and clinical research, providing a sophisticated platform designed to unify and analyze complex clinical trial data. By streamlining data workflows, the company enables pharmaceutical and biotech organizations to improve data integrity and accelerate the decision-making process. In an industry characterized by high regulatory hurdles and fragmented data silos, Rivia serves as a critical infrastructure layer, facilitating faster time-to-market for life-saving therapies through advanced computational analytics and seamless data integration.
How much funding has Rivia raised?
Rivia has raised a total of $18.8M across 2 funding rounds:
Seed
$3.5M
Series A
$15.2M
Seed (2024): $3.5M with participation from Speedinvest
Series A (2026): $15.2M led by Earlybird, Speedinvest, Amino Collective, and Nina Capital
Key Investors in Rivia
Speedinvest
A prominent European venture capital fund with over 1 billion euros in assets under management, specializing in early-stage tech startups across sectors including Health Bio and Deep Tech.
Earlybird
A Berlin-based venture capital firm established in 1997, focused on backing European technology innovators within the medical and broader technology sectors.
Amino Collective
A specialized investment group dedicated to the health and bio sectors, supporting early-stage ventures that aim to scale innovative scientific solutions globally.
What's next for Rivia?
With the successful closure of this major strategic investment, Rivia is poised to scale its enterprise-level operations and deepen its market penetration across Europe and beyond. The company's roadmap likely includes the expansion of its AI-driven analytical suite to address more complex clinical trial requirements and the strengthening of its commercial team to support global pharmaceutical partnerships. As the healthtech landscape continues to prioritize data-driven efficiency, Rivia is well-positioned to capitalize on the increasing demand for automated, high-fidelity clinical research tools, ensuring it remains a pivotal player in the digital transformation of the life sciences industry.
See full Rivia company page
